Equities

Multiplan Corp

MPLN:NYQ

Multiplan Corp

Actions
Health CareHealth Care Providers
  • Price (USD)6.69
  • Today's Change0.24 / 3.72%
  • Shares traded43.96k
  • 1 Year change-86.62%
  • Beta0.5913
Data delayed at least 15 minutes, as of Nov 21 2024 18:39 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy0
Outperform1
Hold2
Sell0
Strong Sell0

Share price forecast in USD

The 3 analysts offering 12 month price targets for Multiplan Corp have a median target of 10.00, with a high estimate of 13.00 and a low estimate of 10.00. The median estimate represents a 55.04% increase from the last price of 6.45.
High101.6%13.00
Med55.0%10.00
Low55.0%10.00

Earnings history & estimates in USD

On Nov 05, 2024, Multiplan Corp reported 3rd quarter 2024 losses of -24.25 per share.
The next earnings announcement is expected on Feb 26, 2025.
Average growth rate-390.09%
Multiplan Corp reported annual 2023 losses of -5.60 per share on Feb 29, 2024.
Average growth rate+392.22%
More ▼

Revenue history & estimates in USD

Churchill Capital Corp III had 3rd quarter 2024 revenues of 230.50m. This missed the 233.67m consensus estimate of the 3 analysts following the company. This was 2.58% below the prior year's 3rd quarter results.
Average growth rate-1.28%
Churchill Capital Corp III had revenues for the full year 2023 of 961.52m. This was 10.95% below the prior year's results.
Average growth rate+1.61%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.